124 results
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
29 May 24
Report of Foreign Private Issuer
7:05am
resurgence of the COVID-19 pandemic and the war between Israel and Hamas; risks related to not satisfying the continued listing requirements of NYSE
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
13 May 24
Report of Foreign Private Issuer
7:03am
-19 pandemic and the war between Israel and Hamas; risks related to not satisfying the continued listing requirements of NYSE American; and statements
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
9 May 24
Report of Foreign Private Issuer
7:03am
the intellectual property rights of others; competitive companies, technologies and our industry; risks related to any resurgence of the COVID-19 pandemic
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
6 May 24
Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602
7:11am
; competitive companies, technologies and our industry; risks related to any resurgence of the COVID-19 pandemic and the war between Israel and Hamas; risks
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
25 Apr 24
Current report (foreign)
7:03am
companies, technologies and our industry; risks related to any resurgence of the COVID-19 pandemic and the war between Israel and Hamas; risks related
6-K
EX-99.1
ps1ww8vtuesvvb1duxl0
15 Apr 24
A pivotal Phase III trial for advanced liver cancer, approved by FDA & EMA and a MASH Phase IIb are enrolling patients
7:03am
POS AM
6f0oo5u v4zs2
5 Apr 24
Prospectus update (post-effective amendment)
4:15pm
6-K
EX-99.1
nfq7s ktcsw
3 Apr 24
Report of Foreign Private Issuer
7:07am
6-K
EX-99.1
blt3oj4m01p
28 Mar 24
Can-Fite Reports 2023 Financial Results and Clinical Update
7:05am
6-K
EX-99.1
pkb4g9qtdbv
11 Mar 24
Report of Foreign Private Issuer
7:27am
6-K
EX-99.1
88or82
28 Feb 24
Patent has already been issued in other major markets including the U.S., EU, Japan and China
7:06am
6-K
EX-99.1
ag8viv1zv7594o t5x6b
30 Jan 24
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
7:24am
6-K
EX-99.1
hd38q a3r3
29 Jan 24
Piclidenoson is a small molecule safe oral drug suitable for the chronic treatment of patients who suffer from moderate to severe plaque psoriasis
7:05am
F-3/A
3in9 pxna
28 Dec 23
Shelf registration (foreign) (amended)
4:16pm
6-K
EX-99.1
5p4wv9j
20 Dec 23
Robust support for Namodenoson’s potential development as an anti-obesity drug, a projected $100 billion market by 2030
7:09am
6-K
EX-99.1
3e78ojq nnffnf
18 Dec 23
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan
7:07am
F-3
vwnrrbu b9ve9x
12 Dec 23
Shelf registration (foreign)
4:15pm
6-K
EX-99.1
jz99 qnipxuog0
4 Dec 23
Report of Foreign Private Issuer
7:05am
6-K
EX-99.1
chg9w0f52rye9tu7itt8
30 Nov 23
Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update
7:05am